 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || CD19-TriCAR-SILK therapy / Timmune Biotech, TI-1007 / Timmune Biotech, Shenzhen Beike Biotech
New P1 trial: Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy (clinicaltrials.gov) - Apr 10, 2019
P1, N=12, Recruiting, Sponsor: Timmune Biotech Inc.
- || CD19-TriCAR-SILK therapy / Timmune Biotech, TI-1007 / Timmune Biotech, Shenzhen Beike Biotech
New P1 trial: Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy (clinicaltrials.gov) - Jan 2, 2019
P1, N=12, Recruiting, Sponsor: Timmune Biotech Inc.
- | TI-1007 / Timmune Biotech, Shenzhen Beike Biotech
New P1 trial, CAR T-Cell Therapy: Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy (clinicaltrials.gov) - Oct 24, 2018
P1, N=6, Recruiting, Sponsor: Timmune Biotech Inc.